Autolus Therapeutics Announces Abstract For Longer-Term Follow-Up And Additional Data Analysis Of Pivotal Phase 2 FELIX Study Of obe-cel For Adult r/r B-ALL Selected For An Oral Presentation At ASCO
Portfolio Pulse from Benzinga Newsdesk
Autolus Therapeutics plc (NASDAQ:AUTL) announced that an abstract from the Phase 2 FELIX study of obe-cel for adult r/r B-ALL has been selected for oral presentation at the 2024 ASCO Annual Meeting. The study focuses on overall survival, event-free survival, and the impact of CAR-T cell persistency and stem cell transplantation. A conference call and webcast to discuss the data will be held on June 1, 2024.
April 24, 2024 | 2:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Autolus Therapeutics' abstract selection for ASCO presentation may positively impact investor sentiment, highlighting progress in obe-cel's development for r/r B-ALL.
The selection of Autolus Therapeutics' abstract for an oral presentation at a prestigious conference like ASCO underscores the significance of the obe-cel study's findings. This visibility could enhance investor confidence in the company's research capabilities and the potential market impact of obe-cel, possibly leading to a positive short-term impact on AUTL's stock price.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100